MS Patients' switch to ozanimod under the microscope
NCT ID NCT05658601
First seen Nov 01, 2025 · Last updated Apr 29, 2026 · Updated 32 times
Summary
This study observed 104 adults with relapsing-remitting multiple sclerosis (RRMS) who had recently switched their disease-modifying therapy to ozanimod. Researchers tracked the reasons for switching—such as lack of effectiveness, side effects, or patient preference—and how the switch was done (e.g., with or without a washout period). The goal was to understand real-world switching patterns, not to test a new treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE SCLEROSIS, RELAPSING-REMITTING are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Local Institution - 0001
Isernia, 86077, Italy
Conditions
Explore the condition pages connected to this study.